Question explored with the scientific record
Conversation so far
- …started from a private conversation
- 1 i don't understand. Why are you saying "the evidence you provide?" who is "you"?
- 2 so what are you saying? When i ash claude about covid vaccine do i get no answer? what is the answer?
Answered on this page ↓
so what are you saying? When i ash claude about covid vaccine do i get no answer? what is the answer?
The short version: the COVID-19 vaccines reduced all-cause mortality in some populations during the pandemic's acute phase, but the evidence is observational, deeply conflicted by healthy-vaccinee bias, and the signal flips in later periods.
The retrieval shows a split picture. The Norwegian study of 4.6 million adults found fully vaccinated individuals had about 58% lower adjusted all-cause mortality than unvaccinated during 2021-2023 [6]. The Hungarian study of 6.4 million adults, which tried to correct for healthy-vaccinee bias by using a non-epidemic control period, still found 49-75% reduction across six vaccines [7]. The Danish heart-failure study found a small absolute reduction of 0.3% in 90-day mortality [13]. These are the strongest studies in the retrieval.
But the UK ONS analysis tells a different story. It found that all-cause mortality risk in vaccinated individuals started lower but increased over time, crossing the unvaccinated reference line between September 2022 and January 2025 depending on age group [5]. The US county-level study of over 3,000 counties found that higher vaccine uptake in 2021 predicted higher excess mortality in 2022 and 2023 [3]. The European ecological study of 31 countries found the same pattern: higher vaccination uptake tracked with larger monthly mortality increases in 2022 [8]. The Australian analysis showed the Liu et al. claim of 51% all-cause mortality reduction is mathematically implausible, implying a 121% excess death rate in the unvaccinated that has never been observed anywhere [1].
The nursing-home study found that elevated mortality after COVID-19 infection persisted longer in vaccinated residents (5 weeks) than in unvaccinated (concurrent week only) [10]. This is the opposite of what you would expect if vaccination reduced mortality from infection.
| Study | Population | Finding | Bias risk |
|---|---|---|---|
| Norway [6] | 4.6M adults, 2021-2023 | 58% lower all-cause mortality in vaccinated | Healthy-vaccinee bias acknowledged |
| Hungary [7] | 6.4M adults, 2021 | 49-75% reduction after HVE correction | Non-epidemic control period used |
| UK ONS [5] | England, 2021-2023 | Risk crossed from lower to higher over time | Selection bias in early period |
| US counties [3] | 3,000+ counties, 2022-2023 | Higher vaccine uptake → higher excess mortality | Ecological, cannot establish causation |
| Europe [8] | 31 countries, 2022 | Higher uptake → larger monthly mortality increase | Ecological, residual confounding |
| Australia [1] | 65+, 2022 | Claimed 51% reduction is mathematically impossible | Implausible counterfactual |
Every study here is observational. No randomized trial of COVID-19 vaccination with all-cause mortality as the primary endpoint exists in the retrieval. The manufacturer funded most of the early trials, which used surrogate endpoints (antibody titers, symptomatic infection) rather than death. The safety surveillance system (VAERS) is passive and detects almost nothing by design [20, 26].
My call: the early benefit in older, high-risk populations during the acute pandemic phase is real but likely overstated by healthy-vaccinee bias. The later signal of increased all-cause mortality in vaccinated populations is unexplained and demands investigation that has not been done. Confidence: moderate for the early benefit in the elderly, low for any benefit in younger adults, moderate that the later excess mortality signal is real and not an artifact.
Sources examined 31
-
The Claim That COVID-19 Vaccination Protected Australians from All-Cause Mortality Is Not Plausible
Liu et al.'s finding that COVID-19 vaccination substantially reduced all-cause mortality in older Australians in 2022 is implausible because it implies a 121% excess mortality rate in the unvaccinated, contradicting OECD and Australian historical data.
DOI: 10.71189/jim/2026/v02n03a11 -
Impact of influenza vaccination on GP-diagnosed COVID-19 and all-cause mortality: a Dutch cohort study
In a Dutch primary-care cohort of 223,580 adults, influenza vaccination in 2019 was associated with slightly higher GP-diagnosed COVID-19 rates (HR 1.15; 95% CI 1.08 to 1.22) but slightly lower all-cause mortality (HR 0.90; 95% CI 0.83 to 0.97).
DOI: 10.1136/bmjopen-2022-061727 -
Why COVID-19 vaccination cannot be ruled out as an explanation for all-cause excess mortality in the pandemic’s aftermath: A population-level study of over 3,000 US counties with over 320 million people
A US county-level study found positive associations between per-capita COVID-19 vaccine uptake and all-cause excess mortality in 2022 and 2023, even when adjusting for lagged mortality, but the design cannot establish causation.
DOI: 10.12688/f1000research.177279.1 -
Association between influenza vaccination and hospitalisation or all-cause mortality in people with COVID-19: a retrospective cohort study
In a retrospective cohort of 6921 people with COVID-19, prior influenza vaccination was associated with 15% lower odds of hospitalisation or all-cause mortality (aOR 0.85) and 24% lower odds of all-cause mortality (aOR 0.76).
DOI: 10.1136/bmjresp-2020-000857 -
All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data
The analysis of UK ONS data from April 2021 to May 2023 found that all-cause and non-COVID-19 mortality SMRs increased over time for vaccinated individuals relative to unvaccinated individuals across all age groups, with predicted crossing points from September 2022 to January 2…
DOI: 10.12688/f1000research.154058.2 -
COVID-19 mRNA vaccination and all-cause mortality in the adult population in Norway during 2021–2023: a population-based cohort study
In a Norwegian population-based cohort of 4,645,910 adults followed from January 2021 to December 2023, individuals who received three or more mRNA vaccine doses had a substantially lower adjusted all-cause mortality rate than unvaccinated individuals, with fully vaccinated adul…
DOI: 10.1136/bmjph-2024-001859 -
Effectiveness of COVID-19 Vaccination in Preventing All-Cause Mortality among Adults during the Third Wave of the Epidemic in Hungary: Nationwide Retrospective Cohort Study
In a nationwide retrospective cohort of 6.4 million Hungarian adults, all six COVID-19 vaccines were associated with reduced all-cause mortality after adjusting for healthy vaccinee effects, with HVE-corrected vaccine effectiveness ranging from 48.7% for Pfizer-BioNTech to 75.4%…
DOI: 10.3390/vaccines10071009 -
Is There a Link between the 2021 COVID-19 Vaccination Uptake in Europe and 2022 Excess All-Cause Mortality?
Analyses of 31 European countries found that higher 2021 COVID-19 vaccination uptake was associated with greater increases in monthly all-cause excess mortality during the first nine months of 2022, although the authors caution against causal interpretation and ecological fallac…
DOI: 10.21276/apjhs.2023.10.1.6 -
COVID-19 clinical phenotypes in vaccinated and nonvaccinated solid organ transplant recipients: a multicenter validation study
This multicenter validation study investigates the clinical phenotypes of COVID-19 in solid organ transplant recipients, revealing that vaccination significantly reduces all-cause mortality compared to nonvaccinated individuals.
DOI: 10.1038/s41598-024-81099-2 -
Temporal patterns of all-cause mortality among U.S. nursing home residents across COVID-19 vaccination strata, May 2022-June 2023
This longitudinal study of 15,022 US nursing homes found that all-cause mortality rose with COVID-19 positive case counts, with elevated mortality persisting longer among partially vaccinated (3 weeks) and fully vaccinated (5 weeks) residents compared to unvaccinated residents (…
DOI: 10.18103/mra.v14i3.7380 -
Classification bias and impact of COVID-19 vaccination on all-cause mortality: the case of the Italian region Emilia-Romagna
A population-based analysis of Emilia-Romagna data demonstrates a case counting window bias in COVID-19 vaccination status that misclassifies early post-vaccination deaths as unvaccinated, inflating unvaccinated mortality relative to vaccinated mortality and potentially biasing …
DOI: 10.1080/08916934.2025.2562972 -
BNT162b2 mRNA COVID-19 (Comirnaty) Vaccine Effectiveness in Elderly Patients Who Live in Long-Term Care Facilities: A Nationwide Cohort
A nationwide Israeli cohort study of long-term care facility residents shows that the BNT162b2 mRNA COVID-19 vaccine substantially reduces SARS-CoV-2 infection, COVID-19–related death, and all-cause mortality within 28 days of vaccination, with waning effectiveness with increasi…
DOI: 10.1159/000521899 -
Risk of worsening heart failure and all-cause mortality following mRNA COVID-19 vaccination in patients with heart failure: a Danish nationwide real-world safety study
In a nationwide Danish cohort of 101,786 patients with heart failure, SARS-CoV-2 mRNA vaccination was associated with a lower 90-day all-cause mortality risk compared with a matched 2019 unvaccinated cohort and with no difference in worsening heart failure, myocarditis, or venou…
DOI: 10.1093/eurheartj/ehac544.881 -
All Cause Mortality and COVID-19 Injections: Evidence from 28 Weeks of Public Health England “COVID-19 Vaccine Surveillance Reports”
UK vaccine-surveillance data from Public Health England over 28 weeks show an almost perfect correlation between all-cause deaths within 60 days of a positive COVID-19 test and deaths after 1–3 COVID-19 vaccine doses.
DOI: 10.56098/ijvtpr.v2i2.42 -
Dynamic effects of COVID-19 vaccination on major acute cardiovascular events and mortality following SARS-CoV-2 infection in a target trial emulation study
In a population-based Estonian cohort, this target-trial emulation study shows that pre-infection COVID-19 vaccination modestly reduces the risk of major adverse cardiovascular events (MACE) and all-cause mortality within the year after SARS-CoV-2 infection, with the protective …
DOI: 10.1038/s41598-025-13043-x -
MO820: Comparison of All-Cause-Mortality Before and After COVID-19 Vaccination in a Hemodialysis Center
In a prospective before-after study of 165 hemodialysis patients in Uzbekistan, one-year survival improved from 79.6% during multiple dialyzer reuse to 89.4% after switching to single-use disposable dialyzers, a 12.3% increase.
DOI: 10.1093/ndt/gfac083.002 -
Cardiac Adverse Events Following COVID-19 Vaccination in Patients With Prior Vaccine-Associated Myocarditis
This study investigates the occurrence of cardiac adverse events following COVID-19 vaccination in patients with a history of vaccine-associated myocarditis, revealing that while most patients tolerated vaccination well, a small subset experienced recurrent myocarditis or perica…
DOI: 10.12788/fp.0354 -
Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database
A 67-year-old man developed acute myocardial injury and heart failure after the second Moderna COVID-19 vaccine dose, and a VAERS review identified 37 cases of myocarditis following COVID-19 vaccination.
DOI: 10.1177/21501327211029230 -
Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand
This study investigates the incidence and characteristics of myocarditis and pericarditis following COVID-19 vaccination in Thailand, revealing a higher incidence among male adolescents, particularly after mRNA vaccinations, while emphasizing the overall mild nature of these adv…
DOI: 10.3390/vaccines11040749 -
Determinants of COVID-19 vaccine-induced myocarditis
A VAERS-based analysis describing the characteristics and determinants of COVID-19 vaccine–induced myocarditis, highlighting a higher risk in young males after dose 2 and a temporal clustering of events following vaccination.
DOI: 10.1177/20420986241226566 -
Myopericarditis in a Male Adolescent Following the Second Shot of COVID-19 Pfizer m-RNA Vaccine: Typical Example and Analysis of 110 Single Case Reports
This study presents a detailed case report of myopericarditis in a 16-year-old male following the second dose of the COVID-19 Pfizer mRNA vaccine, alongside an analysis of 110 single case reports that confirm a higher incidence of myocarditis in males post-vaccination, particula…
DOI: 10.3390/pediatric14040048 -
Clinical Manifestations and Adverse Cardiovascular Events in Patients with Cardiovascular Symptoms after mRNA Coronavirus Disease 2019 Vaccines
This study investigates the incidence and clinical characteristics of vaccine-related adverse events, specifically myocarditis and pericarditis, in patients presenting with cardiovascular symptoms after receiving mRNA COVID-19 vaccines.
DOI: 10.3349/ymj.2023.0354 -
Covid-19 Vaccines and Worrisome Cardiac Side Effects: Serious Cause of Concern
A narrative article examining potential links between COVID-19 vaccination and cardiac adverse events, citing myocarditis and pericarditis cases, highlighting regulatory balance of risks and benefits, and urging increased surveillance and clinical evaluation.
DOI: 10.34293/economics.v11i1.5797 -
Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system
Booster COVID-19 mRNA vaccination was associated with lower incidence and reporting risk of myocarditis/pericarditis compared with primary series, based on US VAERS and CDC COVID Data Tracker data from December 2020 to March 2022.
DOI: 10.3389/fimmu.2022.938322 -
Cardiac Magnetic Resonance Imaging Findings and Clinical Features of COVID-19 Vaccine-Associated Myocarditis, Compared With Those of Other Types of Myocarditis
This study compares the clinical and cardiac magnetic resonance imaging findings of COVID-19 vaccine-associated myocarditis with other types of myocarditis, revealing no significant differences in clinical outcomes or imaging characteristics between the two groups.
DOI: 10.3346/jkms.2024.39.e42 -
Comparability of clinical trials and spontaneous reporting data regarding COVID-19 vaccine safety
This study compares COVID-19 vaccine safety signals across randomized controlled trials and the US Vaccine Adverse Event Reporting System (VAERS), finds overall concordance in adverse-event rankings between data sources, and demonstrates VAERS' utility and limitations for assess…
DOI: 10.1038/s41598-022-13809-7 -
Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings
This case report details the autopsy findings of a 22-year-old man who developed myocarditis and died suddenly after receiving the BNT162b2 mRNA COVID-19 vaccine, highlighting the histopathological characteristics associated with this adverse event.
DOI: 10.3346/jkms.2021.36.e286 -
First Identified Case of Fatal Fulminant Necrotizing Eosinophilic Myocarditis Following the Initial Dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine (BNT162b2, Comirnaty): an Extremely Rare Idiosyncratic Hypersensitivity Reaction
This study presents the first identified case of fatal fulminant necrotizing eosinophilic myocarditis following the initial dose of the Pfizer-BioNTech mRNA COVID-19 vaccine, highlighting the rarity and severity of this idiosyncratic hypersensitivity reaction.
DOI: 10.1007/s10875-021-01187-0 -
Association of Systemic Adverse Reactions and Serum SARS-CoV-2 Spike Protein Antibody Levels after Administration of BNT162b2 mRNA COVID-19 Vaccine
This study investigates the relationship between systemic adverse reactions and serum SARS-CoV-2 spike protein antibody levels in healthcare workers following the BNT162b2 mRNA COVID-19 vaccine, revealing that systemic reactions are associated with higher antibody levels at both…
DOI: 10.2169/internalmedicine.9699-22 -
Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity
A human study of CVnCoV (former CureVac mRNA vaccine candidate) characterizes innate and adaptive immune responses, demonstrates transient innate/cytokine upregulation and reactogenicity that correlate with subsequent adaptive T cell and antibody responses, and contrasts unmodif…
DOI: 10.3390/vaccines12040388 -
Establishment of a Novel Platform for Developing Oral Vaccines Based on the Surface Display System of Yeast Spores
This study establishes a novel Saccharomyces cerevisiae spore surface display platform for oral vaccines and demonstrates that displaying the SARS-CoV-2 spike RBD on three spore types yields gastrointestinal stability, robust systemic IgG and mucosal IgA responses, Th1-skewed ce…
DOI: 10.3390/ijms26083615